Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis

This study has been completed.
Sponsor:
Collaborators:
Forest Laboratories
Information provided by (Responsible Party):
Yvonne C. Lee, Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT01207453
First received: September 21, 2010
Last updated: March 27, 2014
Last verified: March 2014
  Purpose

The purpose of this study is to determine whether milnacipran reduces widespread, non-joint pain in patients with rheumatoid arthritis (RA). The investigators will conduct a double-blind randomized crossover trial in subjects with RA to test the hypothesis that milnacipran improves widespread, non-joint pain. The investigators will also use data from the trial to determine whether response to milnacipran is associated with pain-modulating mechanisms from the central nervous system. The investigators hypothesize that response to milnacipran will be greater among patients with impaired central pain mechanisms than among patients with intact central pain modulating mechanisms.


Condition Intervention Phase
Arthritis, Rheumatoid
Drug: Milnacipran
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis

Resource links provided by NLM:


Further study details as provided by Brigham and Women's Hospital:

Primary Outcome Measures:
  • Change in the Brief Pain Inventory (BPI) Short Form "24-hr average pain" item [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in the diffuse noxious inhibitory control effect (conditioned pain modulation) [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Change in the Symptom Intensity Scale (SIS) score [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Change in the Hospital Anxiety and Depression Scale (HADS) total score [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Change in the Medical Outcomes Study Sleep Problems Index II score [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Change in thumbnail pain threshold [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Change in trapezius pain threshold [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Change in wrist pain threshold [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Change in knee pain threshold [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Other Outcome Measures:
  • Subgroup analyses involving the outcomes of: 1) change in BPI-sf average pain intensity, 2) change in Symptom Intensity Scale score, 3) change in thumbnail pain threshold, 4) change in trapezius pain threshold [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    Subgroup analyses, examining the primary outcome (change in BPI-sf average pain intensity) and selected secondary outcomes (change in Symptom Intensity Scale score, thumbnail pain threshold and trapezius pain threshold), in selected subgroups: 1) BPI-sf average pain intensity >= 4 at baseline, 2) Regional Pain Scale >= 7 at baseline, 3) HADS depression > 7 at baseline, 4) swollen joint count <= 1 at baseline.

  • Clinical characteristics of responders vs. non-responders [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    Descriptive analysis


Enrollment: 49
Study Start Date: January 2011
Study Completion Date: November 2013
Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Milnacipran then placebo
This arm of the study will contain half the study population after randomization. The participants in this arm will receive milnacipran for 6 weeks. They will undergo a one-week taper and a two week washout period and then crossover to a placebo for 6 weeks.
Drug: Milnacipran
Milnacipran comes in 50 mg tablets and is taken orally. Participants will gradually be increased to a target dose of 50 mg twice daily.
Other Name: Savella
Placebo then milnacipran
This arm of the study will contain half the study population after randomization. The participants in this arm will receive placebo for 6 weeks. They will undergo a one-week "taper" and a two week "washout" period and then crossover to milnacipran for 6 weeks.
Drug: Milnacipran
Milnacipran comes in 50 mg tablets and is taken orally. Participants will gradually be increased to a target dose of 50 mg twice daily.
Other Name: Savella

Detailed Description:

Despite the development of effective medications to treat inflammation, pain remains a priority for rheumatoid arthritis (RA) patients. The pain that persists despite anti-inflammatory treatment is usually widespread and non-articular; it may lead to diminished quality of life and high medical, psychological and social costs. To develop better treatments for pain and prevent disability, it is critical to obtain a better understanding of widespread, non-joint pain in RA.

Milnacipran is a selective serotonin-norepinephrine reuptake inhibitor (SNRI). No studies have examined the effect of SNRIs on pain in RA. However, several studies have examined the role of SNRIs in fibromyalgia and related pain conditions. Treatment with milnacipran has been associated with improvements in clinical pain severity in Phase 2 and Phase 3 randomized placebo-controlled trials of fibromyalgia patients. In animal models, milnacipran appears to moderate the pain-inducing effects of inflammation and central sensitization. Thus milnacipran may be an ideal drug to treat pain in RA.

A clinical trial of an SNRI in the treatment of widespread, non-joint pain in RA will provide more information regarding pain mechanisms and may lead to more targeted, effective ways of treating pain in RA.

  Eligibility

Ages Eligible for Study:   24 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 24 years or older
  • Primary diagnosis of rheumatoid arthritis from a board-certified rheumatologist
  • Willing to maintain stable doses of concurrent non-steroidal anti-inflammatory drugs or other acceptable medications or therapies for the duration of the study
  • Brief Pain Inventory Average Pain >= 4 at the screening visit
  • Widespread Pain Index >= 5 at the screening visit
  • Able to give informed consent

Exclusion Criteria:

  • Diagnosis of primary fibromyalgia
  • Diagnosis of cold sensitive conditions such as Raynaud's syndrome, cryoglobulinemia and paroxysmal cold hemoglobinuria
  • Diagnosis of psychotic disorders, such as schizophrenia, schizoaffective disorder, delusional disorder and shared psychotic disorder
  • Patients being treated with SSRIs, MAO inhibitors or tricyclic, tetracyclic or atypical antidepressants for pain may participate in this study if they are washed off these medications before study entry. Patients currently receiving therapy with SSRIs or tricyclic, tetracyclic or atypical antidepressants for depression may be washed off these medications before study entry pending permission of the prescribing physician and if they have never received a diagnosis of major depressive disorder or had a history of suicidal ideation.
  • Patients on thioridazine or MAO inhibitors
  • Patients taking codeine or other opioids/opiates. Patients who are taking medications such as pregabalin (Lyrica) and gabapentin (Neurontin) for pain may be enrolled in this study.
  • Known hypersensitivity to milnacipran
  • Patients with a significant risk of suicide as assessed by the Beck depression inventory form
  • Patients with a history of suicide
  • Pregnant or breast-feeding women
  • Patients with an actively pending worker's compensation claim or auto no-fault claim; patients with current worker's compensation, auto no-fault compensation, or litigation; or any patient with significant secondary gain issues per discretion of the researchers.
  • Patients with myocardial infarction within the past 12 months, active cardiac disease (chest pain or evidence of ischemia on stress test), acute congestive heart failure requiring hospitalization in the past 12 months, clinically significant cardiac rhythm or conduction abnormalities requiring hospitalization in the past 12 months
  • Patients with severe liver impairment (AST or ALT > 3 times the upper limit of normal)

    • For patients 2-3 times the upper limit of normal, we will obtain enrollment permission from the patient's hepatologist and monitor values at each study visit. If values increase above 3 times the upper limit of normal, the patient will be discontinued from the study.
    • For patients 1-2 times the upper limit of normal, we will obtain enrollment permission from the patient's physician and monitor per request of the physician.
  • Patients with severe or end stage renal disease, defined as a GFR < 15 ml/min or on dialysis
  • Patients with a recent (≤ 12 months) history of seizures.
  • Patients with uncontrolled narrow-angle glaucoma.
  • Patients who have been treated with an experimental agent within the last three months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01207453

Locations
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Brigham and Women's Hospital
Forest Laboratories
Investigators
Principal Investigator: Yvonne C Lee, MD, MMSc Brigham and Women's Hospital
  More Information

Publications:
Responsible Party: Yvonne C. Lee, Yvonne C. Lee, MD, MMSc, Brigham and Women's Hospital
ClinicalTrials.gov Identifier: NCT01207453     History of Changes
Other Study ID Numbers: SAV-MD-16, K23AR057578
Study First Received: September 21, 2010
Last Updated: March 27, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Brigham and Women's Hospital:
Arthritis, Rheumatoid
Milnacipran
Pain

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Milnacipran
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin Agents
Physiological Effects of Drugs
Adrenergic Uptake Inhibitors
Adrenergic Agents

ClinicalTrials.gov processed this record on July 29, 2014